XOMA Stock Quote XOMA - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

26.09

Bid

15.77

Ask

30.00

Volume

11,780

25.82 Day's Range 26.79

13.48 52 Week Range 27.00

Market Cap

311.456M

Previous Close

25.82

Open

25.83

Last Trade

26.09

Last Trade Time

Financial Volume

$ 308,730

VWAP

26.2079

Average Volume (3m)

19,081

Shares Outstanding

11,625,826

Dividend Yield

PE Ratio

-7.63

Earnings Per Share (EPS)

-3.51

Revenue

4.76M

Net Profit

-40.83M

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.xoma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

XOMA Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XOMA. The last closing price for XOMA was $25.82. Over the last year, XOMA shares have traded in a share price range of $ 13.48 to $ 27.00.

XOMA currently has 11,625,826 shares outstanding. The market capitalization of XOMA is $311.46 million. XOMA has a price to earnings ratio (PE ratio) of -7.63.

XOMA Corporation Announces Closing of Tender Offer

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech...

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash...

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to...

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments...

XOMA to Present at Upcoming Investor Conferences in March

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the...

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base...

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S...

Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol

By Denny Jacob Xoma will make a $1 million milestone payment to LadRx following the U.S. Food and Drug Administration's acceptance of Zevra Therapeutics' new drug application for...

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.68	6.88242523556	24.41	26.79	24	11160	24.94664618	CS
4	2.08	8.66305705956	24.01	27	23	14134	25.24176382	CS
12	5.3	25.493025493	20.79	27	19.5	19081	24.06711649	CS
26	8.88	51.5979081929	17.21	27	14.27	25276	20.06386299	CS
52	7.4	39.5933654361	18.69	27	13.48	30498	18.51196873	CS
156	-10.89	-29.4483504597	36.98	39.49	13.48	30300	21.48084111	CS
260	13.79	112.113821138	12.3	46.32	11.58	40116	23.04128971	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NIVFNewGenIvf Group Ltd	$ 2.23 (74.22%)	137.08M
MTCMMTec Inc	$ 2.24 (43.59%)	6.07M
OPRTOportun Financial Corporation	$ 3.16 (40.44%)	11.71M
SHIMShimmick Corporation	$ 3.05 (35.56%)	1.19M
HKITHitek Global Inc	$ 1.35 (32.35%)	411.78k
ABEOAbeona Therapeutics Inc	$ 3.39 (-53.94%)	5.51M
GWAVGreenwave Technology Solutions Inc	$ 0.0696 (-44.89%)	37.05M
LICNLichen China Limited	$ 0.56 (-42.19%)	6.61M
MLECMoolec Science SA	$ 1.71 (-30.77%)	3.16M
VAXXVaxxinity Inc	$ 0.1971 (-26.89%)	2.11M
CYNCYNGN Inc	$ 0.113 (-6.61%)	326.58M
PEGYPineapple Energy Inc	$ 0.0561 (22.49%)	185.74M
SQQQProShares UltraPro Short QQQ	$ 11.91 (-4.49%)	139.15M
NIVFNewGenIvf Group Ltd	$ 2.23 (74.22%)	137.08M
TSLATesla Inc	$ 144.68 (1.85%)	124.55M